Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration

Lindström, Torbjörn; Frystyk, Jan; Hedman, Christina A.; Flyvbjerg, Allan; Arnqvist, Hans J.

doi:10.1111/j.1365-2265.2006.02666.x

Cited by 42 publications

(35 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results have been reported in the literature in type I DM [5][6][7][8][9], whereas type II DM has been associated with low serum adiponectin levels [10][11][12][13]. The increase in serum adiponectin levels in type I DM, in contrast to type II DM, may be due to a lack of insulin; glucose and insulin may play an important role in the increased serum adiponectin levels observed in type I DM [5,14] However, Berg et al showed that serum adiponectin levels do not change in mice after the onset of diabetes although the insulin levels decrease dramatically [15].…”

Section: Discussionsupporting

confidence: 80%

“…Studies on DM duration have also not found a relationship between the type I DM duration and serum adiponectin levels [5,16]. However, Lindstrom found that the serum adiponectin levels were increased in patients with a diagnosis of type 1 DM for more than 10 years and stated that this may be due to the disturbed kidney functions related to the duration of DM [8]. Studies have also not found a relationship between metabolic control and the adiponectin levels [19].…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Low Serum Adiponectin Levels in Children and Adolescents with Diabetic Retinopathy

Tasci

Özbek

Önenli-Mungan

et al. 2011

EAJM

View full text Add to dashboard Cite

Objective: The aim of this study was to elucidate the role of adiponectin, leptin, TNF-α and IL-6 on the early detection of the microvascular complications of type I diabetes. Materials and Methods:A total of 88 children were included in the study. There were 60 type I diabetic patients and 28 healthy control children. Results:The gender, age, weight, height, BMI and puberty status characteristics were similar in the patient and control groups (p>0.05). The serum leptin, TNF-α and IL-6 levels were similar between the patient and control groups (p>0.05) and the only diff erence was in the serum adiponectin level which was higher in the patient group (p:0.042). We also found no association between the adiponectin, leptin, TNF-α and IL-6 levels and diabetes duration (p>0.05). Leptin was high in the pubertal period (p:0.016), while adiponectin TNF-α and IL-6 levels were similar in the prepubertal and pubertal periods (p>0.05). The serum leptin level was high in microalbuminuria patients (p<0.041). The serum adiponectin, TNF-α, and IL-6 levels were not diff erent in patients with and without microalbuminuria (p>0.05). The serum adiponectin level was lower in diabetic retinopathy patients (p:0.003), while the serum leptin level was higher (p:0.003). The TNF-α and IL-6 levels were similar in patients with and without retinopathy (p>0.05). Conclusion:We found increased serum adinopectin levels in children and adolescents with type I diabetes mellitus and low levels in diabetic retinopathy patients. Patients with low serum adiponectin levels and high leptin levels should be more closely monitored for chronic complication development and better metabolic control should be aimed for.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 89%

Low Serum Adiponectin Levels in Children and Adolescents with Diabetic Retinopathy

Tasci

Özbek

Önenli-Mungan

et al. 2011

EAJM

View full text Add to dashboard Cite

show abstract

“…Similar results have been obtained with respect to microangiopathy (19,42) and long diabetes duration (43). Unlike C-reactive protein, adiponectin is considered to be inversely related to obesity and dyslipidemia, and low levels have been linked to cardiovascular disease (44,45).…”

Section: Discussionsupporting

confidence: 78%

Metabolic Phenotypes, Vascular Complications, and Premature Deaths in a Population of 4,197 Patients With Type 1 Diabetes

et al. 2008

View full text Add to dashboard Cite

on behalf of the FinnDiane Study Group* OBJECTIVE-Poor glycemic control, elevated triglycerides, and albuminuria are associated with vascular complications in diabetes. However, few studies have investigated combined associations between metabolic markers, diabetic kidney disease, retinopathy, hypertension, obesity, and mortality. Here, the goal was to reveal previously undetected association patterns between clinical diagnoses and biochemistry in the FinnDiane dataset.RESEARCH DESIGN AND METHODS-At baseline, clinical records, serum, and 24-h urine samples of 2,173 men and 2,024 women with type 1 diabetes were collected. The data were analyzed by the self-organizing map, which is an unsupervised pattern recognition algorithm that produces a two-dimensional layout of the patients based on their multivariate biochemical profiles. At follow-up, the results were compared against allcause mortality during 6.5 years (295 deaths). RESULTS-The highest mortality was associated with advanced kidney disease. Other risk factors included 1) a profile of insulin resistance, abdominal obesity, high cholesterol, triglycerides, and low HDL 2 cholesterol, and 2) high adiponectin and high LDL cholesterol for older patients. The highest population-adjusted risk of death was 10.1-fold (95% CI 7.3-13.1) for men and 10.7-fold (7.9 -13.7) for women. Nonsignificant risk was observed for a profile with good glycemic control and high HDL 2 cholesterol and for a low cholesterol profile with a short diabetes duration.CONCLUSIONS-The self-organizing map analysis enabled detailed risk estimates, described the associations between known risk factors and complications, and uncovered statistical patterns difficult to detect by classical methods. The results also suggest that diabetes per se, without an adverse metabolic phenotype, does not contribute to increased mortality. Diabetes 57:2480-2487, 2008 P atients with type 1 diabetes are susceptible to severe microvascular complications such as proliferative retinopathy and chronic kidney disease, which are often accompanied by cardiovascular disease and premature death (1,2). Currently, the risk assessment and diagnostics rely on the urine albumin excretion, serum creatinine, and lipid profile (3,4). In many cases, however, the biochemical measurements are treated as independent factors without explicit attention to the overall metabolic imbalance behind the complications. Although the risk factors for cardiovascular disease and diabetes complications have been verified statistically in large clinical studies (5-7), the overall picture on the mutual relationships and their relevance for risk assessment remains fragmented.The metabolic syndrome (8) is one attempt to describe the co-occurrence of vascular complications and insulin resistance, but so far its applicability to type 1 diabetes and its exact definition remain controversial (9,10). Moreover, gradually developing conditions, such as cardiovascular disease, do not present a physiologically clear border between health and disease, so quanti...

show abstract

“…Our results may provide an explanation for the discrepancy showing that although clinical and animal studies all indicated that APN is cardioprotective, those with type 1 diabetes are more susceptible to myocardial IR and not sensitive to IPo irrespective of increased or decreased APN seen in patients and animals with type 1 diabetes (42,43). Our results showed that loss of the APN cardioprotective effect seen in the late stage of diabetes is largely due to the malfunction of APN, especially the impaired AdipoR1/Cav3 signaling, but not merely the reduction of APN content.…”

Section: Discussioncontrasting

confidence: 41%

Hyperglycemia Abrogates Ischemic Postconditioning Cardioprotection by Impairing AdipoR1/Caveolin-3/STAT3 Signaling in Diabetic Rats

Yao

Liu

et al. 2015

Diabetes

View full text Add to dashboard Cite

Signal transducer and activator of transcription 3 (STAT3) activation is key for ischemic postconditioning (IPo) to attenuate myocardial ischemia-reperfusion injury (MIRI), but IPo loses cardioprotection in diabetes in which cardiac STAT3 activation is impaired and adiponectin (APN) reduced. We found that IPo increased postischemic cardiomyocyte-derived APN, activated mitochondrial STAT3 (mitoSTAT3), improved mitochondrial function, and attenuated MIRI in wild-type but not in APN knockout (Adipo 2/2 ) mice subjected to 30 min coronary occlusion, followed by 2 or 24 h of reperfusion. Hypoxic postconditioning-induced protection against hypoxia/reoxygenation injury was lost in Adipo 2/2 cardiomyocytes but restored by recombinant APN, but this APN beneficial effect was abolished by specific STAT3 or APN receptor 1 (AdipoR1) gene knockdown, or caveolin-3 (Cav3) disruption. APN activated cardiac STAT3 and restored IPo cardioprotection in 4-week diabetic rats where AdipoR1 and Cav3 were functionally interactive but not in 8-week diabetic rats whose cardiac Cav3 was severely reduced and AdipoR1/Cav3 signaling impaired. We concluded that IPo activates mitoSTAT3 through APN/AdipoR1/Cav3 pathway to confer cardioprotection, whereas in diabetes, IPo loses cardioprotection due to impaired APN/AdipoR1/Cav3 signaling. Therefore, effective means that may concomitantly activate APN and repair APN signaling (i.e., AdipoR1/Cav3) in diabetes may represent promising avenues in the treatment of MIRI in diabetes.

show abstract

Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration

Cited by 42 publications

References 34 publications

Low Serum Adiponectin Levels in Children and Adolescents with Diabetic Retinopathy

Low Serum Adiponectin Levels in Children and Adolescents with Diabetic Retinopathy

Metabolic Phenotypes, Vascular Complications, and Premature Deaths in a Population of 4,197 Patients With Type 1 Diabetes

Hyperglycemia Abrogates Ischemic Postconditioning Cardioprotection by Impairing AdipoR1/Caveolin-3/STAT3 Signaling in Diabetic Rats

Contact Info

Product

Resources

About